Procept rises after FDA clears device to treat urinary tract symptoms

PROCEPT BioRobotics

21/08/2024 13:59

** Shares of Procept BioRobotics  PRCT.O  rise 9.6% to
$71.25 premarket 
    ** Medical device maker says the U.S. FDA has cleared its
Hydros Robotic System that uses AI to treat lower urinary tract
symptoms for men with a noncancerous enlargement of the prostate
gland
    ** Lower urinary tract symptoms include trouble urinating or
urinating too often
    ** Up to last close, stock up 55.1% YTD

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))